|
|
|
|
| LEADER |
02807nmm a2200313 u 4500 |
| 001 |
EB000900861 |
| 003 |
EBX01000000000000000697432 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
141202 ||| eng |
| 020 |
|
|
|a 9783709118184
|
| 100 |
1 |
|
|a Lukashevich, Igor S.
|e [editor]
|
| 245 |
0 |
0 |
|a Novel Technologies for Vaccine Development
|h Elektronische Ressource
|c edited by Igor S Lukashevich, Haval Shirwan
|
| 250 |
|
|
|a 1st ed. 2014
|
| 260 |
|
|
|a Vienna
|b Springer Vienna
|c 2014, 2014
|
| 300 |
|
|
|a XIV, 386 p. 35 illus., 33 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines -- Viral-Vectored Vaccines to Control Pathogenic Filoviruses -- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention -- Current Status and Future of Polio Vaccines and Vaccination -- Current Status of Hantavirus Vaccines Development -- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses -- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines -- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines -- Radiovirotherapy for the Treatment of Cancer -- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer -- The Use of Oncolytic Herpesvirus for the Treatment of Cancer -- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines
|
| 653 |
|
|
|a Vaccine
|
| 653 |
|
|
|a Immunology
|
| 653 |
|
|
|a Pharmaceutical technology
|
| 653 |
|
|
|a Immunology
|
| 653 |
|
|
|a Pharmaceutical Sciences/Technology
|
| 653 |
|
|
|a Vaccines
|
| 700 |
1 |
|
|a Shirwan, Haval
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-7091-1818-4?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615.372
|
| 520 |
|
|
|a This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must read” for all those involved in vaccine development, both in academia and industrial vaccine development
|